Phase 2Not yet recruiting
A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Period to Evaluate the Safety, Tolerability, and Efficacy of SAT-3247 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
- Sponsor
- Satellos Bioscience, Inc. (Industry)
- Enrolment
- 51 planned
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- forazapadin; Placebo Comparator
- Ages
- adults, older adults
- Registry
- NCT07872306
Full record on ClinicalTrials.gov
From the registry
This is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD
Primary outcomes
- Safety evaluation of forazapadin in FSHD
- Efficacy of forazapadin as treatment in FSDH
History
Study completion expected
Primary completion expected
Expected to start
Registered